General Authorization Pathway
Coverage may be authorized through either the new-plan current-treatment pathway or when all applicable clinical criteria for the requested indication are met.
ONE of the following
Member is new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days, and medical records document that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.
All applicable clinical criteria for the requested indication are met.
Initial Therapy — Chronic Kidney Disease Anemia
Covered when ALL of the following are met:
ALL of the following
Diagnosis of anemia due to chronic kidney disease.
ONE of the following
Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
Member is stable on one of the ESA agents previously and Hb is ≤ 11.5 g/dL.≤ 11.5 g/dL; dated within the last 60 days
Member is stable on one of the ESA agents previously and Hb is > 11.5 g/dL, with prescriber attestation that the erythropoietin dose will be held or reduced to remain within the appropriate target.> 11.5 g/dL; dated within the last 60 days
Estimated or measured glomerular filtration rate (GFR) is ≤ 60 mL/min.≤ 60 mL/min
For all GFR calculations, use the calculator provided by the National Kidney Foundation.
Member is not receiving hemodialysis.
If the member is receiving hemodialysis, the prescriber must contact the dialysis clinic for the proper billing procedure because the medication is provided by the clinic.
Requested strength is the minimum strength necessary to administer the requested dose.
Initial Therapy — Post-Renal Transplant Anemia
Covered when ALL of the following are met:
ALL of the following
Diagnosis of anemia due to renal transplant.
ONE of the following
Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
Member is not receiving hemodialysis.
If the member is receiving hemodialysis, the prescriber must contact the dialysis clinic for the proper billing procedure because the medication is provided by the clinic.
Initial Therapy — Cancer Chemotherapy Anemia
Covered when ALL of the following are met:
ALL of the following
Diagnosis of anemia due to chemotherapy treatment for cancer.
ONE of the following
Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
Requested strength is the minimum strength necessary to administer the requested dose.
Initial Therapy — HIV Regimen Anemia
Covered when ALL of the following are met:
ALL of the following
Diagnosis of anemia due to a myelosuppressive medication regimen for HIV.
ONE of the following
Requested agent will be used in combination with zidovudine or a zidovudine-containing product.
All other causes of anemia have been ruled out, including iron deficiency, vitamin B12 deficiency, folate deficiency, and hemolysis.
ONE of the following
Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
Initial Therapy — Hepatitis C Regimen Anemia
Covered when ALL of the following are met:
ALL of the following
Diagnosis of anemia due to a myelosuppressive medication regimen for hepatitis C.
ONE of the following
Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
Hb is < 10 g/dL and the member is currently being treated with a hepatitis C regimen containing an interferon product, with or without ribavirin.< 10 g/dL; dated within the last 60 days
Hb is < 10 g/dL, the member is currently being treated with a hepatitis C regimen containing ribavirin without interferon, and ribavirin dose reduction to 600 mg per day has been attempted.< 10 g/dL; dated within the last 60 days
Initial Therapy — Surgery
Covered when ALL of the following are met:
ALL of the following
Indication is to decrease the need for blood transfusion with surgery, including for members who refuse blood donation because of religious beliefs.
Hb is ≤ 13 g/dL.≤ 13 g/dL; dated within the last 30 days
Surgery is planned within the next 3 months.
Document the anticipated date of surgery.
Requested strength is the minimum strength necessary to administer the requested dose.
Initial Therapy — Idiopathic Sideroblastic Anemia or MDS
Covered when ALL of the following are met:
ALL of the following
ONE of the following diagnoses
Idiopathic sideroblastic anemia.
Anemia due to myelodysplastic syndrome (MDS).
ONE of the following
Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
Continuation Therapy — CKD or Post-Renal Transplant
Covered when ANY of the following are met:
ANY of the following
Hb level is < 11.5 g/dL.< 11.5 g/dL; dated within the last 60 days
Hb level is ≥ 11.5 g/dL and the request addresses that the erythropoietin dose will be held or reduced to remain within the appropriate target.≥ 11.5 g/dL; dated within the last 60 days
Continuation Therapy — Sideroblastic Anemia or MDS
Covered when ANY of the following are met:
ANY of the following
Hb level is ≤ 12 g/dL.≤ 12 g/dL; dated within the last 60 days
Hb level is > 12 g/dL and the request addresses that the erythropoietin dose will be held or reduced to remain within the appropriate target.> 12 g/dL; dated within the last 60 days
Continuation Therapy — Cancer Chemotherapy or HIV
Covered when ALL of the following are met:
ALL of the following
Hb level is ≤ 12 g/dL.≤ 12 g/dL; dated within the last 60 days
Requested agent will be used in combination with the causative agent.
Continuation Therapy — Hepatitis C
Covered when the following criterion is met:
Documentation that the member will continue to receive the causative agent.
Coverage under this policy is for the medical benefit. Aranesp, Epogen, and Procrit are also available under the pharmacy benefit; refer to the MassHealth Drug List for pharmacy-benefit coverage and criteria.